With the Evidence
GLP-1 receptor agonists, such as semaglutide (Wegovy or Ozempic) and tirzepatide (Mounjaro), are proven treatments for weight management and type 2 diabetes in the UK when prescribed appropriately. In routine care, titration, follow-up, and what to do after a missed dose should follow the UK product and patient information for your medicine, alongside what you agree with your prescriber, not informal dosing advice from social media. The same active ingredients may be marketed under different names in other countries (for example Zepbound for weight-loss tirzepatide in the United States). Some people still see slower or smaller changes than expected. Below are nine evidence-based reasons why results may vary, grounded in clinical guidance and the research cited at the end of the article.
